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Simple Summary: Anemia is commonly associated with colorectal cancer and often requires in-
tervention with therapeutic iron. However, iron is required for growth by the majority of colonic
bacteria, leading to competition for free luminal iron. Hence, this leaves the potential for the route of
iron administration to lead to differential gut bacterial populations. This study aimed to investigate
the differences in on- and off-tumor bacterial populations following oral and intravenous therapy
in anemic colorectal cancer patients. The following iron therapies were shown to be differential to
bacterial diversity, microbial populations, and predictive metagenomics, inferring that oral iron-
treated patients may have a potentially more procarcinogenic microbiota compared to intravenous
iron-treated patients. Overall, this suggests that intravenous iron may be a more beneficial treatment
for anemia in colorectal cancer, in order to limit microbial perturbations associated with oral iron.
Abstract: Iron deficiency anemia is a common complication of colorectal cancer and may require
iron therapy. Oral iron can increase the iron available to gut bacteria and may alter the colonic
microbiota. We performed an intervention study to compare oral and intravenous iron therapy
on the colonic tumor-associated (on-tumor) and paired non-tumor-associated adjacent (off-tumor)
microbiota. Anemic patients with colorectal adenocarcinoma received either oral ferrous sulphate
(n = 16) or intravenous ferric carboxymaltose (n = 24). On- and off-tumor biopsies were obtained
post-surgery and microbial profiling was performed using 16S ribosomal RNA analysis. Off-tumor
α- and β-diversity were significantly different between iron treatment groups. No differences in
on-tumor diversity were observed. Off-tumor microbiota of oral iron-treated patients showed higher
abundances of the orders Clostridiales, Cytophagales, and Anaeroplasmatales compared to intra-
venous iron-treated patients. The on-tumor microbiota was enriched with the orders Lactobacillales
and Alteromonadales in the oral and intravenous iron groups, respectively. The on- and off-tumor
microbiota associated with intravenous iron-treated patients infers increased abundances of enzymes
involved in iron sequestration and anti-inflammatory/oncogenic metabolite production, compared to
oral iron-treated patients. Collectively, this suggests that intravenous iron may be a more appropriate
therapy to limit adverse microbial outcomes compared to oral iron.
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1. Introduction
Perturbations in gut bacterial populations are characteristic of colorectal cancer, with
the presence of pathogenic indigenous bacterial species at the expense of protective pro-
biotic species [1]. Driver bacteria are involved in the initiation of colorectal cancer. These
driver bacteria are gradually outcompeted by opportunistic passenger bacteria, which have
a selective advantage within the newly defined tumor-microenvironment. These passen-
ger bacteria can potentially either promote or hinder tumor progression, depending on
whether pathogenic or probiotic bacterial populations flourish [2,3]. Alongside this, the
gut microbiota has been shown to be altered in response to many commonly used orally
administered non-antibiotic drugs [4]. Hence, this allows the potential for the route of iron
administration in anemic colorectal cancer patients to lead to differential gut microbial
populations. Therefore, depending upon which bacterial populations thrive, the route of
iron administration may support colorectal cancer progression [2,5].
Iron is essential for the growth and development of the vast majority of gut bacteria,
with pathogenic bacteria tending to have heightened iron acquisition mechanisms [6]. Hence,
in anemic colorectal cancer patients, the use of oral iron supplementation has the potential to
alter bacterial populations of the colorectal tumor-associated (on-tumor) microbiota, as well
as the non-tumor-associated mucosal (off-tumor) microbiota, through increasing gut luminal
iron concentration [7,8]. This may suggest that a parenteral route of iron administration
may be more beneficial to treat anemia, without increasing iron availability to colonic
bacteria. Initial data from the intravenous iron in colorectal cancer associated anemia (IVICA)
trial suggest that intravenous iron may be more beneficial than oral iron in treating pre-
operative anemia [9]. However, results from the preoperative intravenous iron to treat
anemia before major abdominal surgery (PREVENTT) trial has put doubt over the efficacy
of intravenous iron pre-operatively [10]. Hence, the most beneficial treatment of anemia pre-
operatively, oral or intravenous iron, remains uncertain. This study intended to contribute
to the discussion over the route of iron administration in anemic colorectal cancer patients
through assessing the gut microbial outcomes following each iron therapy. We hypothesized
that oral iron would promote a more procarcinogenic gut microbiota, relative to intravenous
iron, potentially through increasing gut luminal iron concentration.
Current research presents conflicting evidence concerning the effect of iron supple-
mentation in murine studies of gut bacterial diversity [11,12]. However, to our knowledge,
a comparison of gut bacterial populations following oral and intravenous iron therapy in
human studies of colorectal cancer has yet to be explored. This pilot intervention study
aimed to compare the outcomes of oral and intravenous iron therapy on the on- and off-
tumor microbiota, in order to assess which therapy is more beneficial to treat anemia in
iron-deficient colorectal cancer patients.
2. Materials and Methods
2.1. Study Population
From the IVICA trial, a total of 40 anemic patients with non-metastatic colorectal ade-
nocarcinoma were randomized to receive either oral ferrous sulphate 200 mg twice a day
(n = 16) or intravenous iron (ferric carboxymaltose—Ferinject™; Vifor Pharma, Glattbrugg,
Switzerland) dosed by weight and hemoglobin in accordance with the summary of product
characteristics (n = 24) [9]. Treatment was administered at least 2 weeks pre-operatively
and anemia was defined as having a hemoglobin level 10 g/L below the sex-specific World
Health Organization definition (women ≤ 120 g/L, men ≤ 130 g/L). The duration of iron
treatment and inclusion hemoglobin for treatment groups are presented in the patient de-
mographics in Table 1. To limit the inclusion of non-iron-deficient anemic individuals, those
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with pre-existing hematological disease, renal failure, or undergoing current chemotherapy
were not eligible for the trial. Colorectal tumor biopsies and paired tumor-adjacent colonic
mucosal tissue biopsies were obtained post-surgery.
Table 1. Patient cohort demographics. Categorical variables are presented with percentages.
Patient Characteristics Oral Iron (n = 16) Intravenous Iron (n = 24)
Age 74.9 (7.4) 74.9 (9.5)
Male 8 (50%) 16 (67%)
Female 8 (50%) 8 (33%)
Height, m 1.66 (0.1) 1.70 (0.09)
Weight, kg 72.7 (17.4) 79.3 (17.3)
Inclusion Hb, g/L 100.3 (10.6) 98.8 (13.1)
Recruitment ferritin, µg/L * 24.5 (11.1–37.3) 23 (10–48.3)
Recruitment transferrin saturation, % * 2.9 (2.5–3.3) 2.8 (2.4–3.3)
Duration of iron treatment, days * 26.5 (15–43) 23.5 (15–40.5)
Tumour Features
Tumour size, mm 48.5 (25.3) 42.4 (23.2)
Tumour Stage
T≤2 1 (6.25%) 3 (12.5%)
T3 10 (62.5%) 18 (75%)
T4 5 (31.25%) 3 (12.5%)
Tumour Location
Right colon 14 (87.5%) 17 (71%)
Left colon 2 (12.5%) 7 (29%)
Preoperative Risk Assessment
ASA fitness status classification
I–II 12 (75%) 10 (42%)
III–IV 4 (25%) 14 (58%)
CR-POSSUM mortality score, % * 3.6 (2.8–9.3) 3.5 (2.6–8.6)
Continuous variables are presented as mean value (standard deviation) or * median value (interquartile range). Hb, Hemoglobin. CR-
POSSUM, ColoRectal Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity. ASA, American Society
of Anesthesiologists.
2.2. DNA Extraction and 16S rRNA Amplicon Sequencing
Microbial DNA was extracted from colorectal tumor biopsies and paired tumor-
adjacent mucosal colonic tissue biopsies using a modified protocol of Qiagen All Prep
DNA/RNA Mini Kit (Qiagen, Hilden, Germany). Biopsies were mechanically lysed using
5-mm steel beads (Qiagen) and 0.1-mm Zirconia/Silica beads (Strateck, Suffolk, UK) with
a TissueLyser (Qiagen), followed by enzymatic and heat lysis. Extracted microbial DNA
was used for 16S ribosomal RNA (rRNA) gene amplification and sequencing to determine
the mucosal-adherent microbiota according to the Earth Microbiome project protocol [13].
Using primers targeted to the V4 region (515F-806R), the 16S rRNA genes were amplified
in technical triplicates. This was performed using a single-step, single-indexed polymerase
chain reaction (PCR). DNA extraction and 16S rRNA gene PCR were both performed in
batch with appropriate multiple reagent-based negative controls. Paired-end sequencing
(2 × 250 base pairs) was completed in a single batch using the Illumina MiSeq platform
(Illumina, San Diego, CA, USA).
2.3. Statistical Analysis
Microbial analysis was performed using the Quantitative Insight into Microbial Ecol-
ogy 2 (QIIME2) pipeline [14]. Bacterial taxonomy was assigned using the Silva-132-99%
operational taxonomic units (OTUs) database [15]. Intra-sample comparisons (α-diversity)
were assessed using the Mann–Whitney U test comparing variation in the abundance-
based coverage estimator (ACE), Chao1, Shannon diversity index, Faith’s phylogenetic
diversity, and observed OTUs. Inter-sample comparisons (β-diversity) were assessed using
permutational multivariate analysis of variance (PERMANOVA) comparing Bray–Curtis
dissimilarity and Jaccard similarity using principal coordinate analysis (PCoA). α-diversity
indices and PCoA were plotted using the R package “ggplot2” [16]. Comparison of relative
abundances of taxa between treatment groups and sample types was performed using a
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linear discriminant analysis (LDA) effect size (LEfSe); taxa with an LDA score greater than
2 with a p-value ≤ 0.05 were considered statistically significant [17]. Predictive functional
profiles from microbial populations were derived using Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States 2 (PICRUSt2), using enzyme classifi-
cation pathway analysis. Differences in predictive enzyme abundances were assessed using
Statistical Analysis of Metagenomic Profiles (STAMP). Corrected q-values were calculated
following multiple testing correction using the Storey false discovery rate. q-values ≤ 0.05
between treatment groups were considered statistically significant [18–20].
3. Results
3.1. On- and Off-Tumor Bacterial Diversity Following Iron Therapy
A total of 7.9 million reads (an average of 109,777 reads/sample) and 2367 features
were obtained following quality control, and a subsampling depth of 8000 reads/sample
was chosen following rarefaction. Comparison of α-diversity metrics shows that patients
treated with oral iron have a significantly higher bacterial diversity (Shannon diversity
and Faith’s phylogenetic diversity), richness (observed OTUs), and abundance (Chao1
and ACE) within their off-tumor microbiota, relative to those treated with intravenous
iron therapy (Figure 1; p < 0.05). Consistent with this, Jaccard similarity and Bray–Curtis
dissimilarity assessed β-diversity between treatment groups and showed that within the
off-tumor microbiota, oral and intravenous iron formed significantly different bacterial
community clusters (Figure 2; p < 0.05).
Figure 1. On- and off-tumor α-diversity is differentially altered following iron therapy. α-diversity
metrics (a) Shannon diversity, (b) abundance-based coverage estimate (ACE), (c) observed operational
taxonomic units (OTUs), (d) Faith’s phylogenetic diversity, and (e) Chao1. Off-tumor diversity metrics
were significantly greater in oral iron compared to intravenous (IV) treated patients. On-tumor
diversity showed no significant differences between oral and IV iron-treated patients (* p ≤ 0.05,
** p ≤ 0.01, ns p > 0.05).
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Figure 2. β-diversity of oral and intravenous iron-treated patients differs between on- and off-tumor
microbiota. Principle coordinate analysis (PCoA) plots based on Jaccard (a,b) and Bray–Curtis
(c,d) distances. Plot ellipses represent 95% confidence incidence for group clusters. The off-tumor
β-diversity shows significantly distinct bacterial community clusters between oral and intravenous
(IV) iron treatments (a; p = 0.046, c; p = 0.027. On-tumour β-diversity shows no significant differences
(ns) between iron treatment (b,d).
The on-tumor microbiota of these patients showed no differences in α-diversity be-
tween iron treatment groups (Figure 1; ns). Along with this, no significant differences in
β-diversity were observed (Figure 2: ns). Taken together, this suggests that oral iron and
intravenous iron-treated patients show significantly different bacterial diversity in their
tumor-adjacent microbiota. However, the tumor-associated microbiota showed a consistent
bacterial diversity between iron treatments.
3.2. Oral and Intravenous Iron-Treated Patients Show Differing Bacterial Communities
Differences in microbial populations between oral and intravenous iron-treated patients
were assessed using LEfSe to determine bacterial taxa that are significantly enriched be-
tween treatments (Figure 3). The off-tumor microbiota of oral iron-treated patients showed
a greater abundance of the Clostridia class, Clostridiales, Anaeroplasmatales, and Cytopha-
gales orders, Lactobacillaceae and Anaeroplasmataceae families, and Lactobacillus, Agathobacter,
Coprococcus 3, Eubacterium eligens group, Eubacterium xylanophilum group, Lachnospiraceae
ND3007 group, Ruminococcaceae NK4A214 group, Ruminococcus 1, Ruminococcus 2, and
Anaeroplasma genera, whereas in the intravenous iron group there was a higher abundance
of the Lachnospiraceae NK4A136 group genus (Figure 3a,b).
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Figure 3. Linear discriminant analysis (LDA) effect size (LEfSe) comparing iron therapy on bacterial taxa in the on- and
off-tumor microbiota. LEfSe cladogram and histogram of LDA scores for differentially abundant bacterial taxa between oral
and intravenous (IV) iron-treated patients in off-tumor (a,b) and on-tumor (c,d) microbiota. Differentially abundant taxa
from phylum to genus taxonomic levels were included. Taxa and nodes highlighted in green were more abundant in oral
and red in IV iron-treated patients. Taxa with an LDA > 2 with a p-value ≤ 0.05 were considered statistically significant.
The on-tumor microbiota in oral iron-treated patients showed a greater abundance of
the Bacilli class, Lactobacillales order, and Prevotella 7, Butyrivibrio, Coprococcus 1, Hungatella,
Lachnospiraceae ND3007 group, Eubacterium ventriosum group, Ruminococcaceae NK4A214
group, and Pleomorphomonas genera, whereas the on-tumor microbiota of intravenous
iron-treated patients showed a higher abundance of the Alteromonadales order and Al-
loprevotella and Enhydrobacter genera (Figure 3c,d). These results suggest that the on- and
off-tumor microbiota show differential responses to iron therapy with oral iron leading to
a more prominent change in bacterial taxa in the tumor-adjacent compared to the tumor-
associated microbiota.
3.3. Differential Predictive Enzymatic Pathways between Iron Treatment Groups
In order to infer the metagenomic pathways associated with microbial profiles, we
performed a PICRUSt2 metagenomic analysis using predicted enzyme classification abun-
dances based on 16S rRNA bacterial populations. These showed a large difference in pre-
dicted microbial enzymes between iron treatments in the off-tumor microbiota (Figure 4a),
while fewer differences in the on-tumor microbiota were observed (Figure 4b). The off-tumor
microbiota were associated with increased abundance of iron-related enzymes, bacterial
non-heme ferritin, and ferric-chelate reductase, in intravenous iron-treated patients com-
pared to oral iron. Along with this, the off-tumor microbiota of intravenous iron-treated
patients showed an increased abundance of enzymes involved in the production of anti-
inflammatory metabolites, including lactaldehyde dehydrogenase and 2-iminobutanoate/2-
iminopropanoate deaminase (Figure 4a).
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Figure 4. Comparison of predictive metagenomics between iron treatment groups. Predictive metagenomic analysis of
enzyme classification abundances between oral and intravenous (IV) iron treatments, based on off-tumor (a) and on-tumour
(b) microbial populations. Corrected q-values were calculated following multiple testing correction using Storey false
discovery rate. q-values ≤ 0.05 were considered statistically significant.
The on-tumor microbiota was associated with an increased abundance of enzymes
involved in anti-inflammatory and colorectal cancer-protective metabolite production,
including cellulose synthase and N-sulfoglucosamine sulfohydrolase, in intravenous iron-
treated patients (Figure 4b). Overall, the predictive metagenomic results suggested that the
on- and off-tumor microbiota profiles associated with intravenous iron-treated patients are
involved in regulating iron metabolism and producing metabolites involved in inhibiting
intestinal inflammatory and colorectal cancer, compared to oral iron-treated patients.
3.4. Paired On- and Off-Tumor Microbiota Show Varying Microbial Communities Following Oral
and Intravenous Iron Therapy
As the tumor-associated and tumor-adjacent microbiota showed differing outcomes
following iron therapy in respect to bacterial taxa, we aimed to assess if the method of iron
administration led to changes between paired on- and off-tumor microbiota (Figure 5a).
Patients treated with oral iron showed their off-tumor microbiota being enriched with the
Bacteroidaceae family and Bacteroides genus, while their on-tumor microbiota showed a higher
abundance of Nocardiaceae, Intrasporangiaceae, and Brevibacteriaceae families and Prevotella 9,
Nocardioides, Kocuria, Brevibacterium, Veillonella, and Catenibacterium genera (Figure 5c,d).
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Figure 5. Paired comparison of on- and off-tumor taxa between treatment groups. LEfSe cladogram and histogram of LDA
scores for differentially abundant bacterial taxa between on- and off-tumor microbiota in oral (a,b) and intravenous (c,d)
iron-treated patients. Taxa and nodes highlighted in red were more significant in the off-tumor microbiota and green in the
on-tumor microbiota. Taxa with an LDA score greater than 2 with a p-value ≤ 0.05 were considered statistically significant.
In contrast, patients treated with intravenous iron showed their off-tumor micro-
biota was enriched with the Firmicutes phylum and Clostridia class, along with a greater
abundance of the Clostridiales and Sphingomonadales orders, the Sphingomonadaceae fam-
ily, and the Paraprevotella genus. Whereas the on-tumor microbiota of patients treated
with intravenous iron showed a higher abundance of the Epsilonbacteraeota phylum,
Campylobacteria class, Campylobacterales order, Campylobacteraceae, Propionibacteriaceae
and Porphyromonadaceae families, and Campylobacter, Porphyromonas, and Cutibacterium
genera (Figure 5a,b). These results suggest that patients treated with oral iron had a more
consistent tumor-associated and tumor-adjacent microbiota, showing only small changes
at lower taxonomic levels, whereas patients treated with intravenous iron showed a much
greater difference between their tumor-associated and tumor-adjacent microbiota, with
major differences at the phylum, class, and order levels.
4. Discussion
A high incidence of colorectal cancer-associated iron deficiency leads to the require-
ment of therapeutic iron to correct anemia, with oral iron being the standard treatment
due to low cost and convenience [21,22]. However, oral iron is associated with gastroin-
testinal side-effects and can increase colonic iron concentration, which has been shown to
contribute to oncogenic signaling and colitis [23–25]. However, to our knowledge, this is
the first study to investigate microbial outcomes of oral iron supplementation in anemic
colorectal cancer patients.
This study demonstrates that the on- and off-tumor microbiota shows differential
outcomes following oral and intravenous iron supplementation, demonstrating differ-
ences in α- and β-diversity, bacterial taxa, and predictive metagenomics. We believe the
biological mechanisms underpinning these differences observed relate to the potential
increase in colonic iron concentration following oral iron administration. This increased
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iron availability to colonic bacteria leads to competition for iron required for growth, with
pathogenic bacteria having heightened iron acquisition mechanism and outcompeting
probiotic bacteria [6]. The colonic iron concentration was not assessed within this study;
however, previous studies have shown that oral iron administration leads to significantly
greater fecal iron concentration compared to intravenous iron administration, supporting
this proposed mechanism [26].
Off-tumor bacterial diversity is significantly different between oral and intravenous
iron treatments, supporting a defined off-tumor microbial profile following each therapy.
A previous study by Thomas et al. [27] showed that α-diversity is significantly increased
in rectal cancer-associated microbiota compared to non-cancerous controls, as well as
showing differentially β-diversity [27]. This suggests that an increased microbial diversity
is potentially required to support cancer. Hence, the increase in off-tumor bacterial diversity
in oral iron-treated patients (Figure 1) may be priming the colonic microbiota to support
further colonic tumor development. In contrast, the on-tumor microbiota were more
consistent between iron treatments, showing no difference in diversity metrics. This may
potentially be due to pre-existing tumor microbial alterations, which may prevent oral
iron from leading to major shifts in bacterial populations away from the cancer-defined
microbiota.
On- and off-tumor bacterial genera that were more abundant in oral iron-treated
patients include Coprococcus, Prevotella, and Ruminococcus (Figure 3a,b). A previous study by
Flemer et al. [28] identified colorectal cancer-enriched microbiota, showing that Coprococcus,
Prevotella, and Ruminococcus were all colorectal cancer-enriched genera [28]. Furthermore, a
study by Kim et al. [29] found that the genera Ruminococcus 2 and Ruminococcaceae NK4A214
group, which were more abundant in oral iron-treated patients (Figure 3a,b), were enriched
in colorectal cancer patient, whereas the genus Lachnospiraceae NK4A136 group, which was
more abundant in intravenous iron-treated patients (Figure 3a), was depleted in colorectal
cancer patients [29]. This suggests that oral iron-treated patients have a greater abundance
of colorectal cancer-enriched genera, whereas intravenous iron-treated patients have a
greater abundance of colorectal cancer-depleted genera, implying oral iron may be utilized
by the colonic microbiota promoting the expansion of cancer-associated bacteria that may
support tumor development, while inhibiting potentially probiotic bacterial populations.
However, what is not stated in these studies is whether these are driver or passenger
bacteria in colorectal cancer.
Beneficial bacterial genera were differentially enriched between iron treatments, po-
tentially including probiotic Lactobacillus which was more abundant in oral iron-treated
patients (Figure 3a), whereas anti-inflammatory acetic and butyric acid-producing Allopre-
votella and Lachnospiraceae NK4A136 group were more abundant in intravenous iron-treated
patients (Figure 3a,b) [30–32]. Collectively, the results of our study are consistent with
previous findings by Lee et al. [26]. The authors showed that the fecal microbiota of oral
and intravenous iron-treated inflammatory bowel disease patients had differential bacterial
communities, supporting the results of our study, with the authors suggesting intravenous
iron may be more beneficial for treating anemic Crohn’s disease patients, in order to limit
microbial perturbations [26].
Predictive metagenomics shows the off-tumor microbiota of intravenous iron-treated
patients has a greater abundance of bacterial enzymes involved in iron metabolism, com-
pared to oral iron (Figure 4). Ferric-chelate reductase is a bacterial enzyme that catalases the
reduction of siderophore-bound ferric iron to release ferrous iron [33]. Bacterial non-heme
ferritin is a storage protein that binds ferrous iron, keeping it inert intracellularly [34].
Collectively, these can contribute to bacterial sequestration of colonic luminal iron. Hence,
it is not biologically available to contribute to colonic inflammation and tumor initia-
tion in the off-tumor colonic mucosa and potentially also sequesters iron away from the
adjacent tumor microenvironment [35]. The off-tumor microbiota of intravenous iron-
treated patients also showed an increased abundance of lactaldehyde dehydrogenase
and 2-iminobutanoate/2-iminopropanoate deaminase. These bacterial enzymes both con-
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verged in pathways involved in lactate/pyruvate production and isoleucine biosynthesis.
These enzymes and pathways are commonly associated with metabolite production in
species of the Lachnospiraceae family, including the Lachnospiraceae NK4A136 group which is
more abundant in intravenous iron treated patients (Figure 3) [32,36]. Lactate and pyru-
vate are both anti-inflammatory metabolites that act to limit colonic inflammation [37–39].
Likewise, isoleucine has also been shown to inhibit intestinal inflammation, as well as
acting to prevent colorectal cancer metastasis [40,41]. The on-tumor microbiota of in-
travenous iron-treated patients shows an increased abundance of cellulose synthase and
N-sulfoglucosamine sulfohydrolase. Cellulose synthase is a bacterial enzyme that produces
cellulose, which can inhibit colonic inflammation through modulating lipid metabolism
and inactivating secondary bile acids [42,43]. Many bacteria of the Proteobacteria phylum
are involved in bacterial biofilm cellulose production utilizing Cellulose synthase. Bacteria
of the Proteobacteria phylum include the Alteromonadales order and Enhydrobacter genus
which are both more abundant in the on-tumor microbiota of intravenous iron-treated
patients (Figure 3) [44,45]. N-sulfoglucosamine sulfohydrolase produces glucosamine,
which is anti-inflammatory and colorectal cancer-protective [46,47]. Collectively, this infers
that the on- and off-tumor microbiota in intravenous iron-treated patients is associated
with iron sequestration, along with anti-inflammatory and tumor protective metabolite
production, compared to oral iron-treated patients. This implies that oral iron treatment
potentially leads to a more procarcinogenic microbiota, due to the loss of protective probi-
otic bacterial populations that provide anti-oncogenic bacterial metabolites to the tumor
microenvironment. However, it is important to note that it remains to be investigated
whether the PICRUSt2 results are functional to further confirm the outcome of this study.
Comparison of paired on- and off-tumor microbiota shows differentially enriched
bacterial taxa in the oral and intravenous iron-treated cohorts (Figure 5). The intravenous
iron group shows substantial differences between the on- and off-tumor microbiota at the
phylum level. In contrast, patients treated with oral iron show relatively few differences,
primarily at the family and genus level. This suggests that oral iron treatment leads to
a more consistent microbiota between cancerous and non-cancerous tissue. In contrast,
intravenous iron-treated patients’ on- and off-tumor microbiota more relevantly reflect the
more diverse bacterial populations typically found between tumor and non-tumor colonic
tissue [28]. The clinical relevance of these differences in bacterial populations following
each therapy has yet to be determined, but has the potential to be utilized as a future
prognostic marker in the management of the disease [48].
This pilot study provided novel insights into microbial outcomes of iron therapy
in colorectal cancer, suggesting oral iron may be a more deleterious microbial-altering
iron therapy, whereas intravenous iron therapy may be more appropriate in this cohort
of anemic patients. Despite the relatively small sample size of this study, significant
differences were observed between iron treatment groups, which can form the foundation
for further large-scale explorative studies. These studies could account for confounding
variables, such as diet, which have the potential to lead to differential microbial populations,
as well as including comparator colonic mucosal microbiota from healthy controls or pre-
iron treatment. The relatively small window of therapeutic intervention in this study may
show differential microbial outcomes compared to longer-term iron therapy. Nevertheless,
this period relevantly reflects the common clinical intervention in anemic colorectal cancer
patients prior to surgery. Furthermore, this study could be further validated through
a more comprehensive study of bacterial metabolomics following iron therapy, as well
as addressing the clinical relevance of differential microbial communities on long-term
outcomes following surgery in these patients.
5. Conclusions
Collectively, this study suggested that the off-tumor microbiota is variable, depending
upon iron supplementation. In contrast, the on-tumor microbiota seem to be more pro-
tected from the influence of iron supplementation, potentially due to pre-existing tumor
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bacterial dysbiosis. Oral iron-treated patients showed more consistent on- and off-tumor
microbiota, whereas intravenous iron-treated patients showed large differences in bacterial
populations between the on- and off-tumor microbiota. Predictive metagenomics from
this study inferred that oral iron-treated patients have potentially more procarcinogenic
on- and off-tumor microbiota compared to intravenous iron-treated patients. This implies
intravenous iron may be a more beneficial to treat anemia in colorectal cancer patients, in
order to prevent the microbial perturbations associated with oral iron supplementation.
Future work should focus on determining the prognostic relevance of the differential gut
bacterial populations following iron supplementation. This has the potential to allow
the development of probiotic therapies to correct bacterial perturbations and potentially
improve clinical outcomes for colorectal cancer patients following surgery.
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